CRISPR’s cardio catch-all drives a biotech’s broad potential

CRISPR’s cardio catch-all drives a biotech’s broad potential

Source: 
Pharma Voice
snippet: 

Scribe uses CRISPR-based platforms to develop one-and-done genetic medicines that could one day head off cardiometabolic diseases and eliminate the need for years of costly and burdensome medical interventions.